Pharma BD Deal Intelligence
Sangamo Therapeutics sold its core delivery platforms out of bankruptcy in a $50 million fire sale, with Eli Lilly picking up the AAV capsid, zinc finger, and MINT platforms plus the ST-506 prion disease program as stalking-horse bidder in a Section 363 court-supervised auction—a distressed-asset rescue, not a strategic bet on Sangamo's standalone value.
Cheap distressed acquisition of a genetic-medicine platform stack
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Sangamo Form 8-K: Chapter 11 filing and asset sale agreements with Lilly and Astellas as stalking-horse bidders.
Sangamo enters asset sale agreement with Eli Lilly for capsid, zinc finger, MINT platforms and ST-506 prion program; Lilly stalking-horse bidder, total…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
As part of Sangamo Therapeutics' Chapter 11 filing, Eli Lilly agreed to acquire Sangamo's AAV capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and the ST-506 prion disease program for $50 million plus assumption of certain liabilities. Lilly serves as the stalking-horse bidder under a Section 363 sale process subject to a court-supervised auction.
Under Sangamo Therapeutics' June 23, 2026 Chapter 11 filing (District of Delaware), Eli Lilly agreed as stalking-horse bidder to acquire Sangamo's core genetic-medicine technology stack — its AAV capsid delivery platform, zinc finger (ZF) platform and modular integrase (MINT) platform — plus the ST-506 prion disease program, for total consideration of $50 million plus assumption of certain liabilities. The bid sets the floor in a court-supervised Section 363 auction and remains subject to higher or better offers.
Amid Sangamo's Chapter 11 filing, Lilly agrees to acquire the capsid/zinc-finger/MINT platforms plus ST-506 for $50M + assumed liabilities as stalking-horse bidder in a §363 sale.
Value is a floor bid in a bankruptcy auction; deal is 'Pending' and could be topped. Platforms are preclinical — value is optionality on Lilly's genetic-medicine ambitions.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Sangamo Therapeutics, Inc. (this deal) | 2026 | $50M | 54 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Gene Therapy deals